AXQ Capital LP Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

AXQ Capital LP bought a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,524 shares of the medical research company’s stock, valued at approximately $693,000.

Other large investors have also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $1,616,000. Nordea Investment Management AB lifted its position in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares in the last quarter. Hickory Asset Management Inc. acquired a new position in IQVIA in the 4th quarter worth approximately $941,000. Fifth Third Bancorp raised its stake in IQVIA by 13.0% during the 4th quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company’s stock valued at $2,590,000 after purchasing an additional 1,521 shares during the period. Finally, Graphene Investments SAS lifted its holdings in shares of IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company’s stock valued at $2,948,000 after purchasing an additional 2,700 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 0.9 %

IQV stock opened at $185.85 on Friday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The company has a 50-day moving average of $194.94 and a two-hundred day moving average of $208.45. The stock has a market capitalization of $32.77 billion, a price-to-earnings ratio of 24.78, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IQV. Stephens initiated coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. Morgan Stanley increased their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Barclays decreased their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Finally, StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.